Document is current
Any future updates will be listed below
-
Authors
Ye, Shanwei
Xu, Qian
Xu, Yong
Lu, Hui
Liu, Zhenfeng
Guo, Jianfeng
Li, Yichuan
Wang, Wei
Ran, Jun
Zhu, Xiaohua https://orcid.org/0000-0003-0495-9510
Zhu, Dongling
Wu, Wei
Yang, Zechuan
Gu, Shiqi
Li, Feng
Qiu, Lugui https://orcid.org/0000-0002-8752-0644
Puré, Ellen https://orcid.org/0000-0003-2107-3711
Bhoj, Vijay G.
Huang, Liang https://orcid.org/0000-0002-8370-3232
Xiong, Wei
Zhang, Zheng https://orcid.org/0000-0002-3242-5738
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82200253)
- License Information
-
More Information
Article History
Received: 27 October 2025
Accepted: 12 June 2026
First Online: 27 June 2026
Ethics
Competing interests: Z.Z., Q.X., Y.X. and F.L. are inventors on a granted patent (CN116083369B) related to the CD19 × CD3 BsAb EV platform. Z.Z., L.H., Q.X., and S.Y. are inventors on two pending patent applications (CN119751688A, CN119751689A) related to the FAP × CD3 BsAb EV platform. These patents are relevant to the technologies described in this manuscript. The remaining authors declare no competing interests.
